Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer

Oncology

Volumn 65, Issue SUPPL. 1, 2003, Pages 18-23

  Bottke, Dirk ^a   Wiegel, Thomas ^a   Höcht, Stefan ^a   Müller, Markus ^a   Schostak, Martin ^a   Hinkelbein, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Prostate cancer; Prostate specific antigen; Radical prostatectomy; Radiotherapy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; CLINICAL TRIAL; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; IATROGENIC DISEASE; IMPOTENCE; INCONTINENCE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RECURRENCE RISK; RELAPSE; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0041912877     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072487     Document Type: Review

References (39)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
2. Zeitman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-833.
3. Catalona WJ, Smith DS: 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
4. Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993;41:113-120.
5. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824.
6. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
7. Lightner DJ, Lange PH, Reddy PK, Moore L: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921-926.
8. van den Ouden D, Bentvelsen FM, Boeve ER, Schroder FH: Positive margins after radical prostatectomy: Correlation with local recurrence and distant progression. Br J Urol 1993;72:489-494.
9. Shekarriz B, Upadhyay J, Wood DP, Hinman J, Raasch J, Cummings GD, Grignon D, Littrup PJ: Vesicourethral anastomosis biopsy after radical prostatectomy: Predictive value of prostate-specific antigen and pathologic stage. Urology 1999;54:1044-1048.
10. Zimmermann FB, Molls M: Three-dimensional treatment planning: Principles and practice. Onkologie 1998;21:474-484.
11. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomized trial. Lancet 1999;353:267-272.
12. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
13. Keisch ME, Perez CA, Grigsby PW, Bauer WC, Catalona W: Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels. Int J Radiat Oncol Biol Phys 1990;19:1503-1506.
14. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. J Clin Oncol 1999;17:1155-1163.
15. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M, Milosevic M: Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001;59:51-60.
16. Coetzee LJ, Hars V, Paulson DF: Postoperative prostate antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996;47:232-235.
17. Hudson MA, Catalona WJ: Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol 1990;143:1174-1177.
18. Link P, Freiha FS, Stamey TA: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991;145:532-534.
19. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-736.
20. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS: The efficacy of postprostatectomy radio-therapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32:317-323.
21. Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T, Porter AT: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997;158:1436-1440.
22. Wiegel T, Hinkelbein W: Locally advanced prostate carcinoma (T2b-T4 N0) without and with clinical evidence of local progression (Tx N+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not? Strahlenther Onkol 1998;174:231-236.
23. Wiegel T, Steiner U, Hinkelbein W: Radiotherapy after radical prostatectomy: Indications, results and side effects. Strahlenther Onkol 1997;173:309-315.
24. Wiegel T, Bottke D, Bandlow P, Steiner U, Hinkelbein W: The value of PSA measurements at 30 Gy, 50 Gy and 60 Gy for dose limitation in patients with radiotherapy for PSA increase after radical prostatectomy. Strahlenther Onkol 2002;178:422-425.
25. Höcht S, Wiegel T, Bottke D, Jentsch H, Sternemann M, Rosenthal P, Hinkelbein W: Computed tomogram prior to prostatectomy. Advantage in defining planning target volumes for postoperative adjuvant radiotherapy in patients with stage C prostate cancer? Strahlenther Onkol 2002;178:134-138.
26. Anscher MS, Clough R, Dodge R: Radiotherapy for a rising prostate specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 2000;48:369-375.
27. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-659.
28. Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
29. Fowler JE Jr, Brooks J, Pandey P, Seaver LE: Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153:1011-1014.
30. Patel A, Dorey F, Franklin J, deKernion JB: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-1445.
31. Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, Schork A, Oesterling JE: Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology 1996;48:40-44.
32. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
33. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel S: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-489.
34. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT: Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-1144.
35. Formenti SC, Lieskovsky G, Simoneau AR, Skinner D, Groshen S, Chen SC, Petrovich Z: Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. J Urol 1996;155:616-619.
36. Van Cangh PJ, Richard F, Lorge F, Castille Y, Moxhon A, Opsomer R, De Visscher L, Wese FX, Scaillet P: Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: Results of a prospective randomized study. J Urol 1998;159:164-166.
37. Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson SK, Larson TR, Ferrigni RG: The results of radical retropubic prostatectomy and adjuvant therapy for pathological stage C prostate cancer. Int J Radiat Oncol Biol Phys 1996;34:535-541.
38. Syndikus I, Pickles T, Kostashuk E, Sullivan LD: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 1996;155:1983-1986.
39. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, Ferrigni RG: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69:613-619.